Centene Corporation Sued for Securities Fraud

Strategic Insights -

Investors in Centene Corporation, a healthcare company that serves consumers in government-sponsored healthcare programs, may have legal options after the company was sued for potential securities law violations. A lawsuit was filed against Centene and its senior executives, alleging that they made false statements about the company's financial guidance and enrollment growth. The stock price of Centene declined significantly after the truth about the company's financial performance was revealed.

Key Takeaways:

  • A lawsuit was filed against Centene Corporation and its senior executives for potential securities law violations.
  • The complaint alleges that Centene made false statements about its financial guidance and enrollment growth.
  • Centene serves consumers in government-sponsored healthcare programs, such as Medicaid and Medicare, and those who purchase insurance through the Affordable Care Act.
  • The company's stock price declined by over 40% after the truth about its financial performance was revealed.
  • The lawsuit is pending in the U.S. District Court for the Southern District of New York.
  • Investors have until September 8, 2025, to ask the Court to be appointed to lead the case.
  • Centene increased its 2025 guidance twice, first on February 4, 2025, and then on April 25, 2025.
  • The company's financial guidance was based on an independent actuarial report from Wakely Consulting Group, which showed lower than expected enrollment growth and increased morbidity rates in 22 of the 29 states Centene serves.
  • The majority of the market that Centene serves was experiencing lower than expected enrollment growth and increased morbidity rates, or frequency of disease and illness.
  • BFA, a leading international law firm representing plaintiffs in securities class actions, is representing the investors in this case.
  • BFA has a history of successful plaintiff law firm cases, including recovering over $900 million in value from Tesla, Inc.'s Board of Directors.
  • Attorney advertising. Past results do not guarantee future outcomes.

Statistics:

  • Centene's stock price fell $22.87 per share, or more than 40%, from $56.65 per share on July 1, 2025 to $33.78 per share on July 2, 2025.
  • The lawsuit alleges that Centene made false statements about its financial guidance, leading to a decline in the company's stock price.
  • 22 of the 29 states that Centene serves were experiencing lower than expected enrollment growth.
  • Morbidity rates in these 22 states were significantly higher than expected.
  • The company's financial guidance was based on an independent actuarial report from Wakely Consulting Group.

Sources:

  • Globe Newswire, July 26, 2025
  • Lawdragon,
  • Chambers USA,
  • The Legal 500,
  • ISS SCAS,
  • National Law Journal,
  • Thomson Reuters,
  • COMTEX_467578290/2010/2025-07-26T07:07:00